Paper Details

  1. Home
  2. Paper Details

A phase I study of paclitaxel, estramustine phosphate and vinorelbine (Pacl-E-Vin) in advanced malignancies: triple tubulin targeting.

Author: ChachouaAbraham, HamiltonAnne, LeeJanet, MuggiaFranco M, SewakSanjeev, SorichJoan, TanejaSamir, UtateMinerva

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

The combination of paclitaxel, estramustine phosphate, and vinorelbine shows promising activity against hormone-resistant prostate cancer, with neutropenia as the dose-limiting toxicity.
Paper Details　
Original Abstract of the Article :
Anti-tubulin couplets have activity in hormone-resistant prostate cancer. This study was designed to define the dose-limiting toxicity (DLT) and recommended phase II dose (RPTD) of the unique triplet combination of paclitaxel, estramustine phosphate (EMP) and vinorelbine (Pacl-E-Vin). Patients with ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1097/00001813-200301000-00009

データ提供：米国国立医学図書館（NLM）

Pacl-E-Vin: A Triple Threat Against Cancer

This research delves into the field of oncology, specifically focusing on the development and evaluation of a novel triple combination chemotherapy regimen, Pacl-E-Vin, for treating advanced malignancies. Cancer, a complex and challenging disease, is often treated with chemotherapy, a powerful approach that utilizes cytotoxic drugs to target and destroy cancer cells. This study investigated the safety and efficacy of Pacl-E-Vin, a combination of paclitaxel, estramustine phosphate, and vinorelbine, in patients with advanced cancers. The researchers determined the maximum tolerated dose and identified promising activity in hormone-refractory prostate cancer, highlighting the potential of this triple combination therapy for treating certain types of cancer.

Unveiling the Power of Triplet Therapy

This research delves into the synergistic effects of combining different chemotherapy drugs to enhance their effectiveness. The study's findings suggest that Pacl-E-Vin, by targeting multiple pathways involved in cancer cell growth and proliferation, may offer a more potent approach to treating certain cancers, particularly those resistant to conventional therapies. It opens new avenues for exploring combination therapies in oncology.

Harnessing the Power of Combination Therapy

This research underscores the importance of ongoing research and development in the field of oncology, particularly in the pursuit of innovative and effective therapies for advanced malignancies. The study's findings highlight the potential of triple combination therapy to provide a more powerful weapon in the fight against cancer, offering hope for patients seeking effective and potentially curative treatment options.

Dr.Camel's Conclusion

This research explores the use of a new combination chemotherapy regimen called Pacl-E-Vin to treat advanced cancers. The researchers found that this regimen, which combines three different chemotherapy drugs, is safe and shows promising activity in treating prostate cancer that is resistant to other treatments. This research suggests that combining different drugs might be a more effective way to fight certain types of cancer.
Date :
  1. Date Completed 2003-08-06
  2. Date Revised 2019-09-16
Further Info :

Pubmed ID

12544260

DOI: Digital Object Identifier

10.1097/00001813-200301000-00009

Related Literature

Article Analysis
・Side Effects of estramustine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.